Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan.
Arashiro, Takeshi
; Arima, Yuzo; Kuramochi, Jin; Muraoka, Hirokazu; Sato, Akihiro; Chubachi, Kumi; Yanai, Atsushi; Arioka, Hiroko; Uehara, Yuki; Ihara, Genei; +22 more...Kato, Yasuyuki; Yanagisawa, Naoki; Ueda, Akihiro; Kato, Hideaki; Oka, Hideaki; Nishida, Yusuke; Nidaira, Yuki; Asami, Takahiro; Jinta, Torahiko; Nakamura, Akira; Oba, Kunihiro; Taniyama, Daisuke; Yamamoto, Kei; Tanaka, Katsushi; Ueshima, Kankuro; Fuwa, Tetsuji; Stucky, Ashley; Suzuki, Tadaki; Smith, Chris; Hibberd, Martin; Ariyoshi, Koya; and Suzuki, Motoi
(2023)
Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan.
Open forum infectious diseases, 10 (6).
ofad240-.
ISSN 2328-8957
DOI: 10.1093/ofid/ofad240
; Arima, Yuzo; Kuramochi, Jin; Muraoka, Hirokazu; Sato, Akihiro; Chubachi, Kumi; Yanai, Atsushi; Arioka, Hiroko; Uehara, Yuki; Ihara, Genei; +22 more...Kato, Yasuyuki; Yanagisawa, Naoki; Ueda, Akihiro; Kato, Hideaki; Oka, Hideaki; Nishida, Yusuke; Nidaira, Yuki; Asami, Takahiro; Jinta, Torahiko; Nakamura, Akira; Oba, Kunihiro; Taniyama, Daisuke; Yamamoto, Kei; Tanaka, Katsushi; Ueshima, Kankuro; Fuwa, Tetsuji; Stucky, Ashley; Suzuki, Tadaki; Smith, Chris; Hibberd, Martin; Ariyoshi, Koya; and Suzuki, Motoi
(2023)
Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan.
Open forum infectious diseases, 10 (6).
ofad240-.
ISSN 2328-8957
DOI: 10.1093/ofid/ofad240
In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined).
-
picture_as_pdf - Arashiro-etal-2023-effectiveness-of-BA1.pdf
-
subject - Published Version
-
- Available under Creative Commons: Attribution-NonCommercial-No Derivative Works 3.0
Downloads